Celularity Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Celularity Inc. (CELU) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.90% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-04-30
- Celularity Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 5.00%.
- Celularity Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.80%, a 91.49% increase year-over-year.
- Celularity Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2021-03-31 was 0.94%.
- Celularity Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.90%, a 11.36% decline from fiscal 2024.
- Celularity Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.40%, a 7.32% increase from fiscal 2023.
- Celularity Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.10%, a 51.85% increase from fiscal 2022.
- Celularity Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.70%, a 237.50% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | 3.90% 10-K · filed 2026-04-30 | ||||
| 2025-09-30 | 4.00% 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | 4.00% 10-Q · filed 2025-08-29 | ||||
| 2024-12-31 | 4.40% 10-K · filed 2026-04-30 | ||||
| 2024-09-30 | 4.50% 10-Q · filed 2025-11-14 | ||||
| 2024-06-30 | 4.90% 10-Q · filed 2025-08-29 | ||||
| 2024-03-31 | 5.00% 10-Q · filed 2025-08-29 | ||||
| 2023-12-31 | 4.10% 10-K · filed 2025-05-08 | ||||
| 2023-09-30 | 4.10% 10-Q · filed 2024-12-06 | ||||
| 2023-06-30 | 4.00% 10-Q · filed 2024-11-07 | ||||
| 2022-12-31 | 2.70% 10-K · filed 2024-07-30 | ||||
| 2022-09-30 | 2.60% 10-Q · filed 2022-11-10 | ||||
| 2022-06-30 | 2.50% 10-Q · filed 2022-08-09 | ||||
| 2022-03-31 | 1.80% 10-Q · filed 2023-05-22 | ||||
| 2021-12-31 | 0.80% 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | 0.80% 10-Q · filed 2021-11-12 | ||||
| 2021-06-30 | 0.88% 10-Q · filed 2021-08-19 | ||||
| 2021-03-31 | 0.94% 10-Q · filed 2021-05-24 | ||||
| 2020-12-31 | 1.00% 10-K · filed 2022-03-31 | 0.41% 10-K/A · filed 2021-05-24 | |||
| 2019-12-31 | 1.73% 10-K/A · filed 2021-05-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |